Search results for Tislelizumab

Tislelizumab Biosimilar – Anti-PDCD1, PD1, CD279 mAb – Research Grade, ProteoGenix, PX-TA1479

Description of Tislelizumab Biosimilar - Anti-PDCD1, PD1, CD279 mAb - Research Grade Introduction Tislelizumab Biosimilar, also known as Anti-PDCD1, PD1, CD279 mAb, is a monoclonal antibody that targets the programmed cell death 1 (PD-1) receptor. This biosimilar is a research grade version of the original Tislelizumab, which is an FDA-approved therapeutic antibody used in the treatment of various cancers. In this article, we will discuss the structure, activity, and potential applications of Tislelizumab Biosimilar. Structure of Tislelizumab Biosimilar Tislelizumab Biosimilar is a fully humanized IgG4 monoclonal antibody that is composed of two heavy chains and two light chains. The heavy chains are made up of four constant regions (CH1, CH2, CH3, and CH4) and one variable region (VH), while the light chains consist of one constant region (CL) and one variable region (VL). The variable regions of both the heavy and light chains are responsible for binding to the PD-1 receptor. Activity of Tislelizumab Biosimilar The primary mechanism of action of Tislelizumab Biosimilar is through its binding to the PD-1 receptor. PD-1 is a cell surface receptor that is expressed on T cells and plays a crucial role in regulating the immune response. When PD-1 binds to its ligands, PD-L1 and PD-L2, it inhibits the activity of T cells, leading to a decrease in immune response. This mechanism is known as immune checkpoint inhibition. Tislelizumab Biosimilar works by blocking the interaction between PD-1 and its ligands, thereby preventing the inhibitory signal and allowing T cells to remain active and attack cancer cells. This leads to an enhanced immune response against cancer cells, ultimately resulting in their destruction. Applications of Tislelizumab Biosimilar Tislelizumab Biosimilar has shown promising results in preclinical studies and is currently being evaluated in clinical trials for the treatment of various types of cancer, including lung cancer, bladder cancer, and liver cancer. As a research grade version, it is primarily used in laboratory settings to study the effects of PD-1 inhibition on the immune response and cancer cells. In addition to its potential as a therapeutic antibody, Tislelizumab Biosimilar also has applications in research and development of other immune checkpoint inhibitors. By studying its structure and activity, scientists can gain a better understanding of the PD-1 pathway and its role in cancer immunotherapy. Conclusion In summary, Tislelizumab Biosimilar is a research grade monoclonal antibody that targets the PD-1 receptor and blocks its inhibitory signal. Its structure, activity, and potential applications make it a valuable tool in the study of cancer immunotherapy and the development of new treatments. Further research and clinical trials are needed to fully understand the potential of Tislelizumab Biosimilar in the treatment of cancer.

Tislelizumab, Abbexa, abx831438

Tislelizumab is a monoclonal antibody biosimilar expressed in CHO cells, targeting PDCD1/PD1/CD279, for use in laboratory research applications. This product is not suitable for use as medicines or in human, therapeutic or diagnostic applications. Tislelizumab (BeiGene) is a humanized monoclonal antibody that was designed to bind to the PD-1 receptor and prevent binding of PD-L1. In addition, tislelizumab was designed to minimize binding to Fc-gamma-receptors (FcyR) on macrophages. Preclinical studies found that binding to FcyR on macrophages compromises the anti-tumor activity of PD-1 antibodies through activation of antibody-dependent macrophage-mediated killing of T effector cells.

Tislelizumab ELISA Kit, ProteoGenix, KPTX255

Description of Tislelizumab ELISA Kit The Structure and Activity of Tislelizumab ELISA Kit Introduction Tislelizumab is a monoclonal antibody that has been developed as a therapeutic agent for the treatment of various types of cancer. It belongs to the class of immune checkpoint inhibitors, which work by targeting specific proteins on immune cells to enhance the body’s natural ability to fight cancer. Tislelizumab has shown promising results in clinical trials and has been approved for use in several countries. Structure of Tislelizumab Tislelizumab is a humanized IgG4 monoclonal antibody, meaning that it is derived from both human and non-human sources. It is composed of two heavy chains and two light chains, held together by disulfide bonds. The antibody has a molecular weight of approximately 150 kDa and is composed of 1317 amino acids. The structure of tislelizumab is designed to specifically bind to a protein called programmed cell death protein 1 (PD-1), which is present on the surface of immune cells. This binding prevents PD-1 from interacting with its ligands, PD-L1 and PD-L2, which are often overexpressed in cancer cells and inhibit the immune response against them. Activity of Tislelizumab The main activity of tislelizumab is to block the interaction between PD-1 and its ligands, thereby releasing the brakes on the immune system and allowing it to attack cancer cells. This mechanism of action is similar to other PD-1 inhibitors such as pembrolizumab and nivolumab. Tislelizumab has also been shown to have a higher binding affinity for PD-1 compared to other PD-1 inhibitors, which may contribute to its efficacy in treating cancer. In addition, it has a longer half-life in the body, allowing for less frequent dosing compared to other PD-1 inhibitors. Application of Tislelizumab ELISA Kit The Tislelizumab ELISA Kit is a diagnostic tool used to measure the levels of tislelizumab in patient samples. It is based on the principle of enzyme-linked immunosorbent assay (ELISA), which involves the use of specific antibodies to detect and quantify a target molecule in a sample. The kit contains all the necessary reagents and materials for the detection of tislelizumab, including a pre-coated plate with immobilized PD-1 protein, biotinylated tislelizumab, streptavidin-HRP conjugate, and a chromogenic substrate. The procedure involves incubating patient samples, along with standards and controls, on the pre-coated plate and detecting the bound tislelizumab using the streptavidin-HRP conjugate and substrate. The Tislelizumab ELISA Kit is a valuable tool for monitoring the levels of tislelizumab in patients receiving treatment, as well as for evaluating the pharmacokinetics and pharmacodynamics of the drug. It can also aid in the development of personalized treatment plans for cancer patients. Conclusion Tislelizumab is a promising new therapy for the treatment of cancer, and its unique structure and mechanism of action make it a valuable addition to the arsenal of immune checkpoint inhibitors. The Tislelizumab ELISA Kit provides a reliable and efficient means of measuring tislelizumab levels in patient samples, making it an essential tool for the development and monitoring of this important therapeutic agent.

Tislelizumab ELISA Kit, Abbexa, abx395144

Tislelizumab ELISA Kit is a quantitative ELISA kit for detection of Tislelizumab.

Tislelizumab Biosimilar - Research Grade, ichor.bio, ICH5004

Detects human PD-1. This non-therapeutic antibody uses the same sequence as the therapeutic antibody Tislelizumab.

Research Grade Tislelizumab (HS870066), abinScience, HS870066